Skip to main content

Advertisement

Inhibitor of DNA binding in heart development and cardiovascular diseases

Article metrics

Abstract

Id proteins, inhibitors of DNA binding, are transcription regulators containing a highly conserved helix-loop-helix domain. During multiple stages of normal cardiogenesis, Id proteins play major roles in early development and participate in the differentiation and proliferation of cardiac progenitor cells and mature cardiomyocytes. The fact that a depletion of Ids can cause a variety of defects in cardiac structure and conduction function is further evidence of their involvement in heart development. Multiple signalling pathways and growth factors are involved in the regulation of Ids in a cell- and tissue- specific manner to affect heart development. Recent studies have demonstrated that Ids are related to multiple aspects of cardiovascular diseases, including congenital structural, coronary heart disease, and arrhythmia. Although a growing body of research has elucidated the important role of Ids, no comprehensive review has previously compiled these scattered findings. Here, we introduce and summarize the roles of Id proteins in heart development, with the hope that this overview of key findings might shed light on the molecular basis of consequential cardiovascular diseases. Furthermore, we described the future prospective researches needed to enable advancement in the maintainance of the proliferative capacity of cardiomyocytes. Additionally, research focusing on increasing embryonic stem cell culture adaptability will help to improve the future therapeutic application of cardiac regeneration.

Background

The mammalian heart is among the earliest formed organs during development. After 6.5 days of the embryonic period (E6.5), the gastrulation-formed mesoderm moves forward in the embryo and at E7.5 forms the cardiac crescent, which is the precursor to the heart. After the myocardial progenitor cells take up residence within the cardiac mesoderm at E7.5, the cardiac crescent can be divided into two layers according to the differential gene expression: the first and the second heart field. The first heart field consists of cardiomyocytes marked by the cardiac transcription factor Nkx2.5 [1]; it begins to undergo the process of differentiation and is surrounded by undifferentiated precursors from the second heart field. The first heart field gives rise to the left ventricle, part of the atria, and the sinus venosus. The second heart field progenitors gradually migrate into the heart tube, differentiating and giving rise to the right ventricle, the rest of the atria and the outflow tract. With the formation of valves and the intermediate septum inside the heart tube, the primitive atria and ventricle are separated and gradually develop into the mature four-chamber cardiac configuration [2]. Precisely controlled gene expression is essential for normal and effective heart function. During the developmental process of the heart, basic helix-loop-helix (bHLH) transcription factors, such as Hey1/2 [3, 4], Hand1/2 [5, 6], Mesp1/2 [7, 8], and Twist1 [9], direct the expression of cardiac genes, thereby playing crucial roles in the regulation of cardiac chamber septation as well as outflow tract and valve morphogenesis. bHLH factors induce transcription as homodimeric or heterodimeric complexes by binding to the target gene at a specific recognition motif in the promoter region, named E-box (CANNTG) or N-box (CACNAG) [10]. Inhibitor of DNA binding (Id) proteins belong to the HLH family of transcription factors, which have an HLH domain but lack a DNA-binding one, thus functioning as negative regulators of bHLH factors through the formation of non-functional HLH-bHLH heterodimers. As transcriptional regulators, four members of the Id family are involved in many pivotal aspects of heart development by competitively forming non-functional heterodimers with other ubiquitously expressed bHLH factors. In this review, we will outline the regulatory role of the Id family components in heart development and cardiovascular diseases and discuss some unsolved questions about their developmental functions.

Overview of the id family

Id proteins, encoded by the Id gene family, consist of Id1, Id2, Id3, and Id4 (Fig. 1). In vertebrates, Id gene family members encode transcription regulators that contain a highly conserved HLH domain but lack a DNA binding domain; therefore, these regulators are unable to bind to DNA directly. Id proteins inhibit gene expression and regulate growth and development by binding to and isolating the ubiquitously expressed E-proteins, Tcf3, Tcf4, and Tcf12 [11,12,13,14,15,16]. Ids are also identified as differential inhibitors according to the effects of differentiation repression [17, 18]. Ids are essential for skeletal myogenesis [19] and cardiac development [20]. Ids also play key roles in the differentiation and proliferation of several cell lineages (such as neural precursor cells [21, 22], B cells [23], regulatory T cells [24], helper T cells [25], retinal progenitor cells [26], cortical precursors [27], myeloid progenitor cells [17, 28], keratinocytes [29, 30], pulmonary artery smooth muscle cells [31], and hair cells during mechanoreceptor organ development [32]), entrainment and operation of the circadian system [33, 34], proliferation of biliary epithelial cells and liver regeneration [35], corpus luteum and vascular remodelling [36], and induction of hormone secretion in melanotrophs [37]. Ids are also involved in multiple diseases, especially in cancers of various organs [38,39,40,41,42].

Fig. 1
figure1

A schematic representation of Id proteins is shown. a, The lack of the ‘basic’ DNA-binding domain makes it impossible for HLH/bHLH heterodimers to bind to DNA directly. b, The black box represents the helix-loop-helix domain, which is important for Id dimerisation with other E proteins

Ids in heart development

Id1

Nearly three decades ago, Id1, the first Id gene, was named after the protein’s ability to inactivate the DNA binding of bHLH transcription factors [43]. In mice, Id1, Id2 and Id3 were reportedly detected in the endo- and epicardium from embryonic day (E) 10.5 through 16.5 [44]. According to a recent study, Id1 is expressed in the most proximal epiblast region of embryos during gastrulation (E6.5–E7.25) and in the anterior lateral mesoderm containing undifferentiated cardiac precursors [45].

Structurally, the depletion of Id1, Id2 or Id3 cannot lead to developmental abnormalities, but double or triple Id knockout embryos (Id1/Id2, Id2/Id3, Id1/Id3 or Id1/Id2/Id3) exhibit severe cardiac defects including valvular and septal defects, outflow tract atresia, impaired ventricular trabeculation and thinning of the compact myocardium layers; the embryos die at mid-gestation [46] (Table 1). Functionally, the expression of Id1 induces apoptosis in cardiac myocytes [47]; however, embryos with Id1–3 deficiency display reduced cell proliferation in the ventricular compact layer. Valvular interstitial cells are yielded from endocardial cells contributing to the cushions of the atrioventricular canal and outflow tract [48, 49]. Using RNA-seq, DeLaughter et al. identified Id1 as a candidate gene important for endocardial epithelial-to-mesenchymal transformation in the chick and mouse embryo [50], which explains the phenotypes of valvular defects and outflow tract atresia seen in Id1 null mice. The expression of the cardiac specific markers, Gata4, α-MHC [51] and Isl1 [52], are upregulated in P19CL6 cells transfected with Id1 during cardiac differentiation and Id1 can promote proliferation of these cells in vitro [53]. Similarly, Id1 is needed for normal cardiogenic mesoderm differentiation in mouse embryonic stem cells (ESCs) and is sufficient to direct ESCs to differentiate towards the cardiac mesoderm [45]. Thus, despite functional redundancy, Id1 regulates differentiation of cardiac precursors and is involved in proliferation and apoptosis of cardiomyocytes.

Table 1 Developmental phenotypes of Id-knockout animal model

Id2

Id2 mRNA can be detected in the extraembryonic but not in the embryonic ectoderm from E6.5 onwards. In the developing heart, Id2 expression can be seen in the developing cardiac neural crest, outflow tract, and inflow tract, as well as in the neurons surrounding the developing aorta, pulmonary artery, the epicardium and the endocardium from E10.5, but it is absent in the myocardium [46]. Id2 is expressed in the nascent atrioventricular bundle at E12.5 and in the bundle branches at E16.5 [54].

Although no cardiac phenotype was mentioned in previous studies, Moskowitz et al. found that more than 20% of Id2 null mice died, and atrioventricular septal defects and membranous ventricular septal defects were observed in these mutant perinatal deaths [55] (Table 1). In addition to its significant function in cardiogenesis, which has been demonstrated using single or multiple Ids knockout animal models in vivo and by using ESCs in vitro (Id2−/−, Id1−/−Id2−/−, or Id1−/−Id2+/−Id3−/−), structurally [56, 57] Id2 plays a key role in the specification of ventricular myocytes into the ventricular conduction system lineage. Electrocardiography on Id2-null mice displays ventricular conduction delay, with a widened QRS complex (RsR’ pattern) in lead I, aVL, and V6, indicative of a left bundle branch block. Histologically, the atrioventricular bundle and left bundle branch seem normal but display reproducible patterning abnormalities [54] (Table 1).

Id3

Expression of Id3 can be found in both the embryonic ectoderm and the extraembryonic endoderm at E5.5. From mid-gastrulation, Id1 and Id3 expression exists in partially overlapping patterns in the endocardial cushion (EC) mesenchyme and in the epicardium and endocardium from E10.5; it persists in the endocardium, endothelium, epicardium and cardiac valves until postnatal day 7 [46, 58].

Because of the functional overlap, single Id3 knockout mice do not show any phenotype during the developmental process [46], which complicates the elucidation of the underlying functions.

Id4

Compared with the expression patterns of the other three Id genes, Id4 expression differs from the widespread expression of Idl, Id2, and Id3 in the embryo [44, 59, 60]. Id4 is absent from heart and functionally isolated [44, 46]; thus, it used to be considered irrelevant to heart development.

Until recently, Id4 was found to be expressed in the developing atrioventricular canal endocardium and in the adult atrial chamber in zebrafish embryos during atrioventricular valve formation. Id4−/− embryonic hearts exhibit impaired atrioventricular valve function (retrograde blood flow from the ventricles to the atria) and reduced endocardial cells contributing to the AV valves [61] (Table 1). To further uncover the potential function of Id genes in early mammalian heart formation, Cunningham et al. generated an Id1–4 quadruple genetically ablated mouse model and observed an absence of heart tube formation at E8.25, when the heart tube should have normally formed, in contrast with Id1–3 triple mutants [45] (Table 1). However, a heart tube can still be formed with only one Id4 wild-type allele, indicating the crucial role of Id4 in early heart formation.

Regulators of id gene expression

BMP signalling pathway

Heart development is a multistep process that involves precise regulation by multiple signalling pathways during embryogenesis, such as bone morphogenetic proteins (BMP) [62, 63] and their downstream targets, Ids. Crossveinless-2, a BMP binding protein [64], is expressed in P19 cells earlier than the cardiac transcription factors Nkx2.5 and Tbx5 and serves as an inhibitor for BMP signalling. Crossveinless-2 can bind to BMP and antagonize its activity, inhibiting the phosphorylation of the Smad1/5/8 complex and downregulating Id1 expression, consequently increasing the induction of cardiac cells [65]. Similarly, the p204 protein enables the differentiation of P19 cells to cardiomyocytes by overcoming inhibition by Id proteins [66].

In another study, a Tie2-Cre mouse was crossed with a BMP receptor type 1a (BMPR1a) floxed mouse to generate a cKO model. In BMPR1a-cKO hearts, atrioventricular valves and adjacent septa failed to form, and expression of Id1/3 was absent from the embryonic atrioventricular canal (AVC) region, suggesting that Bmpr1a expression is needed for AV valve formation and Id1/3 expression in this area [67] (Fig. 2). Activin receptor type-1b (Acvr1b), also named Alk-4, functions as a transducer of activin in the TGF-beta signalling pathway and plays an important role in early endoderm formation [68,69,70,71]. The knockdown of Acvr1b using siAcvr1b induces Id1/3 expression in ESCs. As Id1/3 expression increases, early cardiogenic mesoderm markers (Evx1 and Mesp1) [8, 72, 73] are upregulated, and cardiogenic mesoderm formation is induced. Ids are not able to bind to target genes directly; Cunningham et al. demonstrated that this induction of cardiac mesoderm is directed by repressing two mesoderm formation inhibitors—Tcf3 and Foxa2 [74, 75] as well as by activating Evx1, Grrp1, and Mesp1 [45] (Fig. 2).

Fig. 2
figure2

The evidence to date of the differing regulation of Ids in epicardium (a), ventricular conduction system myocytes (b), cardiomyocytes (c), P19 cells (d), endocardium (e) and ES cells (f) is shown

Smad4 is believed to be a central and essential factor regulating Bmp signalling [76]. After binding to signal ligands, Bmp receptors promote the phosphorylation of Smad1/5/8. With the combination of phosphorylated Smad1/5/8 and Smad4, this complex is able to regulate downstream transcription regulators involved in cardiac development, such as Ids [77]. Smad4 cooperates with Gata4 to activate the Id2 promoter and regulate cardiac valve development, while mutations in Smad4 and/or Gata4 abrogate this activity and lead to endocardial cushion followed by atrioventricular septal defects [55] (Fig. 2). As a direct downstream target transcription factor of Smad4 playing various roles during cardiogenesis and during the development of multiple organs [77], Mycn is indispensable to ventricular wall morphogenesis. Mycn enhances cardiomyocyte proliferation through the regulation of Id2 expression. The cardiomyocyte specific knockout of Mycn downregulates the expression of Id2 and reduces cell proliferation in mutant ventricles [78].

Wnt signalling pathway

Wnt signalling is required for heart development [79,80,81,82]. Injection of ESCs into preimplantation Id KO embryos prevents cardiac defects and corrects 85% of misregulated gene expression profiles throughout the heart due to upregulated expression of Wnt5a in epicardial cells [83]. Furthermore, in P19CL6 cells transfected with Id1, cardiac specific markers, such as Gata4, α-MHC and Isl1 as well as the Wnt signalling pathway components Wnt3a and β-catenin [84] are upregulated and cardiac differentiation and proliferation are induced, while treatment with LiCl (lithium chloride) or Wnt3a upregulates Id1 expression in the same cell lineage, which is indicative of a positive feedback loop between Id1 and Wnt signalling [53] (Table 2, Fig. 2).

Table 2 Developmental function and regulation of Ids in different cell lineage in vitro

The inactivation of Id4 in zebrafish embryos causes the downregulation of multiple genes crucial for AV canal and AV valve formation, including spp1, and elevates Wnt/β-catenin signalling to delay the maturation of valvular cells through the inhibition of TCF activity [61].

IGF signalling pathway

In an endocardium- and endothelium-specific Id1/3 conditional knockout (cKO) mouse model (Tie2-Cre) [85], cardiac enlargement, and ventricular septal defects were observed in neonatal mice, while fibrotic vasculature and decreased cardiac function were observed in adult ones. Insulin-like growth factor binding protein-3 (IGFbp3) [86], a suppressor of Id proteins, can rescue and reverse gene expression profiles in Id1/3 cKO hearts [87].

To rescue the developmental defects caused by Id1–3 KO, ESCs were injected into preimplantation Id KO embryos. ESCs could partially rescue heart defects through two secreted factors, insulin-like growth factor I (IGFI) [88] and Wnt5a [89] (Fig. 2). IGFI expression overlaps with Id, promotes the proliferation of cardiomyocytes [90], and is downregulated in Id KO epicardial cells. IGFI from ESCs can be released into the Id KO embryos, reversing some of the cardiac defects [83]. However, the reversal is not completely effective.

Cardiac transcription factors

In the ventricular conduction system, both in vivo and in vitro analyses confirmed that Nkx2.5 and Tbx5, two key cardiac transcription factor genes, are necessary for Id2 expression in the conduction system cardiomyocytes. Id2 has a functional binding site in its promoter for Tbx5 and is a downstream regulatory target of Tbx5 and Nkx2.5.This transcriptional network controls the differentiation balance of the conduction system by inhibiting cardiac muscle gene expression and promoting gene expression specificity pointing to the ventricular conduction system [54] (Fig. 2).

Ids in cardiovascular diseases and regenerative medicine

Congenital heart disease

Congenital heart disease (CHD) is a common malformation related to multiple congenital anomalies, and the mutation of key gene loci or fragments in the development of the heart plays an important role in the occurrence and development of such diseases. Increasing evidence has shown the association of the abnormal expression of Id genes with CHD in animal models [46, 87]. According to Molck’s study, clinically significant copy number variations (CNVs≥300 kb) were detected in patients with congenital heart diseases. ID2 (located in 2p25.1), one of the genes known to participate in cardiac development, was found inside the CNV region of a patient suffering from atrial and ventricular septal defects, pulmonary atresia, and transposition of the great arteries (14,838 kb duplication in 2p24.3-p25.3), which indicates the likely association of ID2 gene defects in human CHD [91].

Arrhythmia

The cardiac conduction system functions to initiate and propagate electrical impulses to maintain sequential and effective myocardial contraction. Disorders of the cardiac electrophysiological system are often at the origin of arrhythmias. Id2 expression has been detected in the atrioventricular bundle and bundle branches of mice, and it regulates the differentiation of cardiac precursors towards conduction system cell lineage; Id2-deficient mice show intraventricular conduction delay [54]. Id2 is not only involved in the development of the ventricular conduction system in rodents but also affects electrical signalling in the human atrium. A novel genome-wide association was identified with PR interval, a measure of atrial depolarization and atrioventricular conduction, and a single nucleotide polymorphism (SNP) at ID2 (rs6730558) was confirmed to be associated with prolonged PR interval in Asian, African and European populations. Such a change may lead to atrial fibrillation, heart failure and cardiac mortality [92].

Coronary artery pathology

Coronary artery pathology is the leading cause of death worldwide. In addition to adverse lifestyles, genetic variation plays an important role in the occurrence and progression of coronary artery pathology [93]. In humans, ID3 and its SNP (rs11574, related to carotid intima-media thickness) have been demonstrated to be associated with coronary heart disease, as measured by coronary artery calcium, a predictor of coronary disease burden [94], and with atheroma burden by intravascular ultrasound [95] in non-Hispanic White, African American, and Hispanic populations [96, 97]. A meta-analysis on five datasets from the GEO series provides further evidence that ID3 is associated with coronary heart disease [98]. The finding that the ID3 gene is associated with coronary artery pathology can be supported by the fact that Id3 is an atheroprotective transcription regulator which functions to regulate B cell homing and B cell–mediated protection from early atherosclerosis. Furthermore, ID3 reduces atherosclerosis formation [99,100,101], in addition to T cell differentiation and maturation, which has been demonstrated as playing an important role in atherosclerosis [24].

Heart regeneration

Cardiac regeneration has been considered as the most thorough and promising treatment for mocardial injury due to various causes, but this strategy is limited by the extremely low proliferation capacity of mature myocardial cells in post-mitotic state. [102,103,104]. It has been proposed that fetal cardiomyocytes and progenitor cells have could be used for the development of a potential cell-based therapy, owing to their proliferative stem cell characteristics [105, 106]. The possibility of clinically effective therapies for myocardial damage using primary fetal cardiomyocytes is supported by the current evidence demonstrating that Id1, Id2, and Id3 have implications for the maintenance of the proliferative capacity of human fetal ventricular cardiomyocytes [107]. Another option for inducing cell proliferation and heart regeneration is to reprogram cardiomyocytes into the cell cycle via the delivery of specific stimulators is another option to induce cell proliferation for heart regeneration. A cocktail of three mitosis-related genes, FoxM1, Id1, and Jnk3-shRNA, was delivered to induce cardiomyocytes to re-enter the cell cycle and undergo mitosis in vitro. This method successfully increased the proliferation of cardiomyocytes in vivo and reversed cardiac dysfunction after myocardial infarction [108].

Id1 also plays an important role in maintaining the growth activity of embryonic stem cells. Embryonic stem cells provide an indispensable resource for the development of cell-based regenerative medicine [109]. Three genes in chromosome 20q11.21, ID1, BCL2L1, and HM13, are related to culture adaptation of human ES cells [110], thereby providing a strong growth advantage in ES cells, which is highly likely to have a positive effect on subsequent cell differentiation, cardiomyocyte renewal, and heart regeneration.

Future perspectives

Single-cell RNA sequencing, a disruptive technology to explore differential gene expression among single cells, has been widely used in development research in multiple organs, including the heart [111,112,113]. By tracking and sequencing the gene expression of individual Id-expressing cells at different stages, we can fully understand the physiological function of these genes in the process of cardiac development. Similarly, the use of cell classification technology to sequence cell lineages with different fate determinations at the same development stage and compare the expression heterogeneity among cell types horizontally can also deepen the recognition of the distribution and function of Ids.

All four known Id proteins play roles in heart development; Id1–3 share some degree of overlap in terms of expression range and developmental function, but Id4 shows a distinct side [46, 59]. According to Sharma’s study, ID4 heterodimerizes with ID1/2/3 and acts as an inhibitor of ID1–3 proteins; this interaction dependent on helix-loop-helix domain of ID4 [114]. At present this finding has not yet been confirmed in cardiomyocytes. If it is true, then the isolated expression areas of Id4 and Id1–3 can be explained. Likewise, Id4 might be upregulated and compensate for missing functions in Id1/2/3 KO mouse embryos, under circumstance of being repressed by the other three Ids.

The immune system makes an irreplaceable contribution to heart development, composition and function [115]. As previously mentioned, Ids are essential for the differentiation and proliferation of B cells [23], regulatory T cells [24], and helper T cells [25]. Despite no evidence for involvement in the development of coronary arteries as macrophages [116], both B cells and T cells modulate wound healing and tissue repair after myocardial injury [117, 118]. Whether Ids can induce heart repair and regeneration through the regulation of B cell and T cell differentiation and proliferation is well worth further exploration. Additionally, Id1- and Id3-expressing cardiac progenitors give rise to the epicardium, a layer of mesothelial tissue that enfolds the heart; this has been considered as a new source in cardiac repair and regeneration [119], providing another theoretical basis.

Id2 has demonstrated the involvement of the specification of ventricular myocytes into the ventricular conduction system lineage in mice, while depletion of Id2 leads to intraventricular conduction delay [54]. However, the SNP in ID2 (rs6730558) was identified as related to the PR interval in humans [92], indicative of that Id2 is implicated in normal conduction of cardiac electrical signals through the atrium. Given that the expression of Id2 is exclusive from the sinoatrial node and atrial conduction system [120], we may reasonably reach the hypothesis that Id2 regulates the development of the atrial conduction system through an undiscovered signalling pathway or regulatory network.

Circadian biological activity manifests itself as regular behavior in time. Most organs of eukaryotes have their own biological cycles, and their activities are regulated by the biological clock [121]. Both genetic factors and environmental agents are involved in the regulation of this circadian change in 24-h temporal patterns during the day and at night [122]. The transcriptional repressor Id2, for example, plays a crucial role in circadian rhythms [34]. The rhythm impulse that heart pacemaker cell sends is affected by the circadian clock [123], in addition to the requirement of Id2 for cardiac conduction system development [54], which brings the possibility that Id2 regulates circadian rhythm of the heart rate variability.

Conclusion

In the present article, we provide a comprehensive review of the research to date regarding the role of Id proteins in heart development and the related cardiovascular diseases. During embryonic development, Ids play major roles in early cardiogenesis and during the entire process of the differentiation and proliferation of multiple myocardial cell types, including working cardiomyocytes, endocardial myocardium, epicardial myocardium, and conduction system cells. These physiological functions of Ids are regulated by growth factors and multiple signalling pathways, including Bmp and Wnt, in a cell- and tissue- specific manner to affect heart development (Fig. 2, Fig. 3). The roles of individual Ids in the development of the different tissues and cell lineages of the heart remain to be fully elucidated; however, by tracking and sequencing the gene expression of individual Id-expressing cells at different stages as well as cell lineages with different fate determinations at the same development stage, scientific researchers can fully understand the physiological roles of these genes in the process of cardiac development. Recent studies of Ids have provided tremendous insights into the molecular mechanisms of cardiovascular disease, including congenital structural, coronary, and arrhythmogenic heart disease. Further investigation is needed to determine whether Ids can induce heart repair and regeneration through the regulation of B cell and T cell differentiation and proliferation or though the epicardium that arises from Id1- and Id3-expressing cardiac progenitors. Additionally, Id1 is implicated in the maintenance of the proliferative capacity of human fetal ventricular cardiomyocytes, the reprogramming of mature cardiomyocytes to re-enter cell cycle and regain proliferation capacity, and an increase in ES cell culture adaptability, all of which are indicative of the therapeutic potential for cardiac regeneration.

Fig. 3
figure3

A summary of the regulation network of Ids in heart development is shown. In cardiogenesis, Ids play an important role by regulating the transcription and expression of a variety of key cardiac factors and these regulatory functions are regulated by various signalling pathways and transcription factors. As direct downstream targets of the BMP-Smad signalling pathway, Ids are also regulated by Wnt and IGF signalling pathways. Tbx5 and Nkx2.5, two cardiac transcription factors, also regulate Id to mediate the specification of ventricular myocytes into the ventricular conduction system lineage

Abbreviations

Acvr1b:

Activin receptor type-1b

AVC:

atrioventricular canal

bHLH:

basic helix-loop-helix

BMP:

bone morphogenetic proteins

BMPR1a:

BMP receptor type 1a

CHD:

congenital heart disease

cKO:

conditional knockout

CNV:

copy number variations

E:

embryonic day

EC:

endocardial cushion

Id:

Inhibitor of DNA binding

IGFbp3:

Insulin-like growth factor binding protein-3

SNP:

single nucleotide polymorphism

References

  1. 1.

    Pashmforoush M, Lu JT, Chen H, Amand TS, Kondo R, Pradervand S, Evans SM, Clark B, Feramisco JR, Giles W, et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell. 2004;117:373–86.

  2. 2.

    Abu-Issa R, Kirby ML. Heart field: from mesoderm to heart tube. Annu Rev Cell Dev Biol. 2007;23:45–68.

  3. 3.

    Fischer A. Hey genes in cardiovascular development. Trends Cardiovasc Med. 2003;13:221–6.

  4. 4.

    Kokubo H, Miyagawa-Tomita S, Johnson RL. Hesr, a mediator of the notch signaling, functions in heart and vessel development. Trends Cardiovasc Med. 2005;15:190–4.

  5. 5.

    Srivastava D, Cserjesi P, Olson EN. A subclass of bHLH proteins required for cardiac morphogenesis. Science. 1995;270:1995–9.

  6. 6.

    Srivastava D. HAND proteins: molecular mediators of cardiac development and congenital heart disease. Trends Cardiovasc Med. 1999;9:11–8.

  7. 7.

    Kitajima S, Takagi A, Inoue T, Saga Y. MesP1 and MesP2 are essential for the development of cardiac mesoderm. Development. 2000;127:3215–26.

  8. 8.

    Bondue A, Blanpain C. Mesp1: a key regulator of cardiovascular lineage commitment. Circ Res. 2010;107:1414–27.

  9. 9.

    VanDusen NJ, Firulli AB. Twist factor regulation of non-cardiomyocyte cell lineages in the developing heart. Differentiation. 2012;84:79–88.

  10. 10.

    De Masi F, Grove CA, Vedenko A, Alibes A, Gisselbrecht SS, Serrano L, Bulyk ML, Walhout AJM. Using a structural and logics systems approach to infer bHLH-DNA binding specificity determinants. Nucleic Acids Res. 2011;39:4553–63.

  11. 11.

    Barone MV, Pepperkok R, Peverali FA, Philipson L. Id proteins control growth induction in mammalian cells. Proc Natl Acad Sci U S A. 1994;91:4985–8.

  12. 12.

    Christy BA, Sanders LK, Lau LF, Copeland NG, Jenkins NA, Nathans D. An id-related helix-loop-helix protein encoded by a growth factor-inducible gene. Proc Natl Acad Sci U S A. 1991;88:1815–9.

  13. 13.

    Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994;8:1270–84.

  14. 14.

    Jen Y, Weintraub H, Benezra R. Overexpression of id protein inhibits the muscle differentiation program: in vivo association of id with E2A proteins. Genes Dev. 1992;6:1466–79.

  15. 15.

    Kee BL. E and ID proteins branch out. Nat Rev Immunol. 2009;9:175–84.

  16. 16.

    Yang CY, Best JA, Knell J, Yang E, Sheridan AD, Jesionek AK, Li HS, Rivera RR, Lind KC, D'Cruz LM, et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol. 2011;12:1221–9.

  17. 17.

    Kreider BL, Benezra R, Rovera G, Kadesch T. Inhibition of myeloid differentiation by the helix-loop-helix protein id. Science. 1992;255:1700–2.

  18. 18.

    Norton JD, Deed RW, Craggs G, Sablitzky F. Id helix—loop—helix proteins in cell growth and differentiation. Trends Cell Biol. 1998;8:58–65.

  19. 19.

    Biederer CH, Ries SJ, Moser M, Florio M, Israel MA, McCormick F, Buettner R. The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development. J Biol Chem. 2000;275:26245–51.

  20. 20.

    Springhorn JP, Ellingsen O, Berger HJ, Kelly RA, Smith TW. Transcriptional regulation in cardiac muscle. Coordinate expression of id with a neonatal phenotype during development and following a hypertrophic stimulus in adult rat ventricular myocytes in vitro. J Biol Chem. 1992;267:14360–5.

  21. 21.

    Nagata Y, Todokoro K. Activation of helix-loop-helix proteins Id1, Id2 and Id3 during neural differentiation. Biochem Biophys Res Commun. 1994;199:1355–62.

  22. 22.

    Riechmann V, Sablitzky F. Mutually exclusive expression of two dominant-negative helix-loop-helix (dnHLH) genes, Id4 and Id3, in the developing brain of the mouse suggests distinct regulatory roles of these dnHLH proteins during cellular proliferation and differentiation of the nervous system. Cell Growth Differ. 1995;6:837–43.

  23. 23.

    Sun XH. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell. 1994;79:893–900.

  24. 24.

    Maruyama T, Li J, Vaque JP, Konkel JE, Wang W, Zhang B, Zhang P, Zamarron BF, Yu D, Wu Y, et al. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. Nat Immunol. 2011;12:86–95.

  25. 25.

    Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, Deng L, Zanvit P, Tu E, Jin W, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells. Nat Immunol. 2015;16:1077–84.

  26. 26.

    Du Y, Yip HK. The expression and roles of inhibitor of DNA binding helix-loop-helix proteins in the developing and adult mouse retina. Neuroscience. 2011;175:367–79.

  27. 27.

    Ross SE, Greenberg ME, Stiles CD. Basic Helix-loop-Helix factors in cortical development. Neuron. 2003;39:13–25.

  28. 28.

    Ko J, Patel N, Ikawa T, Kawamoto H, Frank O, Rivera RR, Van Etten RA, Murre C. Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proc Natl Acad Sci U S A. 2008;105:12967–72.

  29. 29.

    Alani RM, Hasskarl J, Grace M, Hernandez HC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix–loop–helix protein, Id-1. Proc Natl Acad Sci U S A. 1999;96:9637–41.

  30. 30.

    Simbulan-Rosenthal CM, Trabosh V, Velarde A, Chou FP, Daher A, Tenzin F, Tokino T, Rosenthal DS. Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation. Oncogene. 2005;24:5443–58.

  31. 31.

    Yang J, Li X, Li Y, Southwood M, Ye L, Long L, Al-Lamki RS, Morrell NW. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2013;305:L312–21.

  32. 32.

    Kamaid A, Neves J, Giraldez F. Id gene regulation and function in the prosensory domains of the chicken inner ear: a link between bmp signaling and Atoh1. J Neurosci. 2010;30(34):11426.

  33. 33.

    Duffield GE, Watson NP, Mantani A, Peirson SN, Robles-Murguia M, Loros JJ, Israel MA, Dunlap JC. A role for Id2 in regulating photic entrainment of the mammalian circadian system. Curr Biol. 2009;19:297–304.

  34. 34.

    Ward SM, Fernando SJ, Hou TY, Duffield GE. The transcriptional repressor ID2 can interact with the canonical CLOCK components CLOCK and BMAL1 and mediate inhibitory effects on mPer1 expression. J Biol Chem. 2010;285:38987–9000.

  35. 35.

    Choi TY, Khaliq M, Tsurusaki S, Ninov N, Stainier DYR, Tanaka M, Shin D. Bone morphogenetic protein signaling governs biliary-driven liver regeneration in zebrafish through tbx2b and id2a. Hepatology. 2017;66:1616–30.

  36. 36.

    Nio-Kobayashi J, Narayanan R, Giakoumelou S, Boswell L, Hogg K, Duncan WC. Expression and localization of inhibitor of differentiation (ID) proteins during tissue and vascular remodelling in the human corpus luteum. Mol Hum Reprod. 2013;19:82–92.

  37. 37.

    Konishi H, Ogawa T, Nakagomi S, Inoue K, Tohyama M, Kiyama H. Id1, Id2 and Id3 are induced in rat melanotrophs of the pituitary gland by dopamine suppression under continuous stress. Neuroscience. 2010;169:1527–34.

  38. 38.

    Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003;13:410–8.

  39. 39.

    de Candia P, Benera R, Solit DB. A role for id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res. 2004;92:81–94.

  40. 40.

    Roschger C, Cabrele C. The id-protein family in developmental and cancer-associated pathways. Cell Commun Signal. 2017;15:7.

  41. 41.

    Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer. 2014;14:77–91.

  42. 42.

    Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene. 2001;20:8326–33.

  43. 43.

    Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990;61:49–59.

  44. 44.

    Jen Y, Manova K, Benezra R. Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev Dyn. 1996;207:235–52.

  45. 45.

    Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang CT, Bushway PJ, Tierney M, Albini S, Giacca M, et al. Id genes are essential for early heart formation. Genes Dev. 2017;31(13):1325–38.

  46. 46.

    Fraidenraich D, Stillwell E, Romero E, Wilkes D, Manova K, Basson CT, Benezra R. Rescue of cardiac defects in id knockout embryos by injection of embryonic stem cells. Science. 2004;306:247–52.

  47. 47.

    Tanaka K, Pracyk JB, Takeda K, Yu ZX, Ferrans VJ, Deshpande SS, Ozaki M, Hwang PM, Lowenstein CJ, Irani K, et al. Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism. J Biol Chem. 1998;273:25922–8.

  48. 48.

    Mulholland DL, Gotlieb AI. Cell biology of valvular interstitial cells. Can J Cardiol. 1996;12:231–6.

  49. 49.

    Shworak NW. Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways? Curr Opin Cardiol. 2004;19:140–6.

  50. 50.

    DeLaughter DM, Christodoulou DC, Robinson JY, Seidman CE, Baldwin HS, Seidman JG, Barnett JV. Spatial transcriptional profile of the chick and mouse endocardial cushions identify novel regulators of endocardial EMT in vitro. J Mol Cell Cardiol. 2013;59:196–204.

  51. 51.

    Tanigawa G, Jarcho JA, Kass S, Solomon SD, Vosberg HP, Seidman JG, Seidman CE. A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell. 1990;62:991–8.

  52. 52.

    Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647–53.

  53. 53.

    Meng Q, Jia Z, Wang W, Li B, Ma K, Zhou C. Inhibitor of DNA binding 1 (Id1) induces differentiation and proliferation of mouse embryonic carcinoma P19CL6 cells. Biochem Biophys Res Commun. 2011;412:253–9.

  54. 54.

    Moskowitz IP, Kim JB, Moore ML, Wolf CM, Peterson MA, Shendure J, Nobrega MA, Yokota Y, Berul C, Izumo S, et al. A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell. 2007;129:1365–76.

  55. 55.

    Moskowitz IP, Wang J, Peterson MA, Pu WT, Mackinnon AC, Oxburgh L, Chu GC, Sarkar M, Berul C, Smoot L, et al. Transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac valve development. [corrected]. Proc Natl Acad Sci U S A. 2011;108:4006–11.

  56. 56.

    Florholmen G, Andersson KB, Yndestad A, Austbo B, Henriksen UL, Christensen G. Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. Acta Physiol Scand. 2004;180:133–42.

  57. 57.

    Lim JY, Kim WH, Kim J, Park SI. Induction of Id2 expression by cardiac transcription factors GATA4 and Nkx2.5. J Cell Biochem. 2008;103:182–94.

  58. 58.

    Liu KJ, Harland RM. Cloning and characterization of Xenopus Id4 reveals differing roles for id genes. Dev Biol. 2003;264:339–51.

  59. 59.

    Riechmann V, Vancruchten I, Sablitzky F. The expression pattern of Id4, a novel dominant-negative Helix-loop-Helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994;22:749–55.

  60. 60.

    van Cruchten I, Cinato E, Fox M, King ER, Newton JS, Riechmann V, Sablitzky F. Structure, chromosomal localisation and expression of the murine dominant negative helix-loop-helix Id4 gene. Biochim Biophys Acta. 1998;1443:55–64.

  61. 61.

    Ahuja S, Dogra D, Stainier DYR, Reischauer S. Id4 functions downstream of bmp signaling to restrict TCF function in endocardial cells during atrioventricular valve development. Dev Biol. 2016;412:71–82.

  62. 62.

    Kruithof BP, Duim SN, Moerkamp AT, Goumans MJ. TGFbeta and BMP signaling in cardiac cushion formation: lessons from mice and chicken. Differentiation. 2012;84:89–102.

  63. 63.

    Schultheiss TM, Burch JB, Lassar AB. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev. 1997;11:451–62.

  64. 64.

    Jumabay M, Zhumabai J, Mansurov N, Niklason KC, Guihard PJ, Cubberly MR, Fogelman AM, Iruela-Arispe L, Yao Y, Saparov A, et al. Combined effects of bone morphogenetic protein 10 and crossveinless-2 on cardiomyocyte differentiation in mouse adipocyte-derived stem cells. J Cell Physiol. 2018;233:1812–22.

  65. 65.

    Harada K, Ogai A, Takahashi T, Kitakaze M, Matsubara H, Oh H. Crossveinless-2 controls bone morphogenetic protein signaling during early cardiomyocyte differentiation in P19 cells. J Biol Chem. 2008;283:26705–13.

  66. 66.

    Ding B, Liu CJ, Huang Y, Yu J, Kong W, Lengyel P. p204 protein overcomes the inhibition of the differentiation of P19 murine embryonal carcinoma cells to beating cardiac myocytes by id proteins. J Biol Chem. 2006;281:14893–906.

  67. 67.

    Kaneko K, Li X, Zhang X, Lamberti JJ, Jamieson SW, Thistlethwaite PA. Endothelial expression of bone morphogenetic protein receptor type 1a is required for atrioventricular valve formation. Ann Thorac Surg. 2008;85:2090–8.

  68. 68.

    Poulain M, Furthauer M, Thisse B, Thisse C, Lepage T. Zebrafish endoderm formation is regulated by combinatorial nodal, FGF and BMP signalling. Development. 2006;133:2189–200.

  69. 69.

    Gu ZY, Nomura M, Simpson BB, Lei H, Feijen A, van den Eijnden-van Raaij J, Donahoe PK, Li E. The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. Genes Dev. 1998;12:844–57.

  70. 70.

    Chen YM, Mironova E, Whitaker LL, Edwards L, Yost HJ, Ramsdell AF. ALK4 functions as a receptor for multiple TGF beta-related ligands to regulate left-right axis determination and mesoderm induction in Xenopus. Dev Biol. 2004;268:280–94.

  71. 71.

    Colas AR, McKeithan WL, Cunningham TJ, Bushway PJ, Garmire LX, Duester G, Subramaniam S, Mercola M. Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis. Genes Dev. 2012;26:2567–79.

  72. 72.

    Kalisz M, Winzi M, Bisgaard HC, Serup P. EVEN-SKIPPED HOMEOBOX 1 controls human ES cell differentiation by directly repressing GOOSECOID expression. Dev Biol. 2012;362:94–103.

  73. 73.

    Bondue A, Lapouge G, Paulissen C, Semeraro C, Iacovino M, Kyba M, Blanpain C. Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell Stem Cell. 2008;3:69–84.

  74. 74.

    Spieker N, Peterson J, Reneman S, Destree O. Analysis of the Tcf-3 promoter during early development of Xenopus. Dev Dyn. 2004;231:510–7.

  75. 75.

    Howard L, Mackenzie RM, Pchelintsev NA, McBryan T, McClure JD, McBride MW, Kane NM, Adams PD, Milligan G, Baker AH. Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Res Ther. 2013;4:36.

  76. 76.

    Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233–41.

  77. 77.

    Song L, Yan W, Chen X, Deng CX, Wang Q, Jiao K. Myocardial smad4 is essential for cardiogenesis in mouse embryos. Circ Res. 2007;101:277–85.

  78. 78.

    Harmelink C, Peng Y, DeBenedittis P, Chen H, Shou W, Jiao K. Myocardial Mycn is essential for mouse ventricular wall morphogenesis. Dev Biol. 2013;373:53–63.

  79. 79.

    Wu X. Wg signaling in Drosophila heart development as a pioneering model. J Genet Genomics. 2010;37:593–603.

  80. 80.

    Rochais F, Mesbah K, Kelly RG. Signaling pathways controlling second heart field development. Circ Res. 2009;104:933–42.

  81. 81.

    Gessert S, Kuhl M. The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ Res. 2010;107:186–99.

  82. 82.

    Tian Y, Cohen ED, Morrisey EE. The importance of Wnt signaling in cardiovascular development. Pediatr Cardiol. 2010;31:342–8.

  83. 83.

    Fraidenraich D, Benezra R. Embryonic stem cells prevent developmental cardiac defects in mice. Nat Clin Pract Cardiovasc Med. 2006;3(Suppl 1):S14–7.

  84. 84.

    Marinou K, Christodoulides C, Antoniades C, Koutsilieris M. Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab. 2012;23:628–36.

  85. 85.

    Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230–42.

  86. 86.

    Cubbage ML, Suwanichkul A, Powell DR. Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. J Biol Chem. 1990;265:12642–9.

  87. 87.

    Zhao Q, Beck AJ, Vitale JM, Schneider JS, Gao S, Chang C, Elson G, Leibovich SJ, Park JY, Tian B, et al. Developmental ablation of Id1 and Id3 genes in the vasculature leads to postnatal cardiac phenotypes. Dev Biol. 2011;349:53–64.

  88. 88.

    Martin JL, Baxter RC. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem. 1986;261:8754–60.

  89. 89.

    Clark CC, Cohen I, Eichstetter I, Cannizzaro LA, McPherson JD, Wasmuth JJ, Iozzo RV. Molecular cloning of the human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to chromosome 3p14-p21. Genomics. 1993;18:249–60.

  90. 90.

    Scharin Tang M, Redfors B, Lindbom M, Svensson J, Ramunddal T, Ohlsson C, Shao Y, Omerovic E. Importance of circulating IGF-1 for normal cardiac morphology, function and post infarction remodeling. Growth Hormon IGF Res. 2012;22:206–11.

  91. 91.

    Molck MC, Simioni M, Paiva Vieira T, Sgardioli IC, Paoli Monteiro F, Souza J, Fett-Conte AC, Felix TM, Lopes Monlleo I, Gil-da-Silva-Lopes VL. Genomic imbalances in syndromic congenital heart disease. J Pediatr. 2017;93:497–507.

  92. 92.

    Seyerle AA, Lin HJ, Gogarten SM, Stilp A, Mendez Giraldez R, Soliman E, Baldassari A, Graff M, Heckbert S, Kerr KF, et al. Genome-wide association study of PR interval in Hispanics/Latinos identifies novel locus at ID2. Heart. 2017.

  93. 93.

    Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet. 2006;7:163–73.

  94. 94.

    Hecht HS. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging. 2015;8:579–96.

  95. 95.

    Kilic ID, Caiazzo G, Fabris E, Serdoz R, Abou-Sherif S, Madden S, Moreno PR, Goldstein J, Di Mario C. Near-infrared spectroscopy-intravascular ultrasound: scientific basis and clinical applications. Eur Heart J Cardiovasc Imaging. 2015;16:1299–306.

  96. 96.

    Beineke P, Fitch K, Tao H, Elashoff MR, Rosenberg S, Kraus WE, Wingrove JA, Investigators P. A whole blood gene expression-based signature for smoking status. BMC Med Genet. 2012;5:58.

  97. 97.

    Manichaikul A, Rich SS, Perry H, Yeboah J, Law M, Davis M, Parker M, Ragosta M, Connelly JJ, McNamara CA, et al. A functionally significant polymorphism in ID3 is associated with human coronary pathology. PLoS One. 2014;9:e90222.

  98. 98.

    Shi Y, Yang S, Luo M, Zhang WD, Ke ZP. Systematic analysis of coronary artery disease datasets revealed the potential biomarker and treatment target. Oncotarget. 2017;8:54583–91.

  99. 99.

    Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, Skaflen MD, Cutchins A, Lee DJ, Glover DK, Kelly KA, et al. B-cell aortic homing and atheroprotection depend on Id3. Circ Res. 2012;110:e1–12.

  100. 100.

    Lipinski MJ, Campbell KA, Duong SQ, Welch TJ, Garmey JC, Doran AC, Skaflen MD, Oldham SN, Kelly KA, McNamara CA. Loss of Id3 increases VCAM-1 expression, macrophage accumulation, and atherogenesis in Ldlr−/− mice. Arterioscler Thromb Vasc Biol. 2012;32:2855–61.

  101. 101.

    Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, Tsimikas S, Witztum JL, Bender TP, McNamara CA. Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol. 2013;33:2771–9.

  102. 102.

    Porrello ER, Olson EN. A neonatal blueprint for cardiac regeneration. Stem Cell Res. 2014;13:556–70.

  103. 103.

    Leone M, Magadum A, Engel FB. Cardiomyocyte proliferation in cardiac development and regeneration: a guide to methodologies and interpretations. Am J Physiol Heart Circ Physiol. 2015;309:H1237–50.

  104. 104.

    van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. Nat Med. 2014;20:1386–93.

  105. 105.

    Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763–76.

  106. 106.

    Goldman BI, Wurzel J. Effects of subcultivation and culture medium on differentiation of human fetal cardiac myocytes. In Vitro Cell Dev Biol. 1992;28A:109–19.

  107. 107.

    Ball AJ, Levine F. Telomere-independent cellular senescence in human fetal cardiomyocytes. Aging Cell. 2005;4:21–30.

  108. 108.

    Cheng YY, Yan YT, Lundy DJ, Lo AH, Wang YP, Ruan SC, Lin PJ, Hsieh PC. Reprogramming-derived gene cocktail increases cardiomyocyte proliferation for heart regeneration. EMBO Mol Med. 2017;9:251–64.

  109. 109.

    Zhang Y, Mignone J, MacLellan WR. Cardiac regeneration and stem cells. Physiol Rev. 2015;95:1189–204.

  110. 110.

    International Stem Cell I, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29:1132–44.

  111. 111.

    Li G, Xu A, Sim S, Priest JR, Tian X, Khan T, Quertermous T, Zhou B, Tsao PS, Quake SR, et al. Transcriptomic profiling maps anatomically patterned subpopulations among single embryonic cardiac cells. Dev Cell. 2016;39:491–507.

  112. 112.

    DeLaughter DM, Bick AG, Wakimoto H, McKean D, Gorham JM, Kathiriya IS, Hinson JT, Homsy J, Gray J, Pu W, et al. Single-cell resolution of temporal gene expression during heart development. Dev Cell. 2016;39:480–90.

  113. 113.

    Ishida H, Saba R, Kokkinopoulos I, Hashimoto M, Yamaguchi O, Nowotschin S, Shiraishi M, Ruchaya P, Miller D, Harmer S, et al. GFRA2 identifies cardiac progenitors and mediates cardiomyocyte differentiation in a RET-independent signaling pathway. Cell Rep. 2016;16:1026–38.

  114. 114.

    Sharma P, Chinaranagari S, Chaudhary J. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, −2 and −3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity. Biochimie. 2015;112:139–50.

  115. 115.

    Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018.

  116. 116.

    Leid J, Carrelha J, Boukarabila H, Epelman S, Jacobsen SE, Lavine KJ. Primitive embryonic macrophages are required for coronary development and maturation. Circ Res. 2016;118:1498–511.

  117. 117.

    Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res. 2015;116:354–67.

  118. 118.

    Forte E, Furtado MB, Rosenthal N. The interstitium in cardiac repair: role of the immune-stromal cell interplay. Nat Rev Cardiol. 2018;15:601–16.

  119. 119.

    Cao J, Poss KD. The epicardium as a hub for heart regeneration. Nat Rev Cardiol. 2018;15:631–47.

  120. 120.

    Christoffels VM, Moorman AF. Development of the cardiac conduction system: why are some regions of the heart more arrhythmogenic than others? Circ Arrhythm Electrophysiol. 2009;2:195–207.

  121. 121.

    Bollinger T, Schibler U. Circadian rhythms - from genes to physiology and disease. Swiss Med Wkly. 2014;144:w13984.

  122. 122.

    Buhr ED, Takahashi JS. Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. 2013:3–27.

  123. 123.

    Lakatta EG, Maltsev VA, Vinogradova TM. A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ Res. 2010;106:659–73.

Download references

Acknowledgements

The authors gratefully acknowledge financial support from the China Scholarship Council.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Author information

WH contributes to literature search, figures, study design, and drafting the manuscript. YX contributes to literature search. JH contributes to design of the review. YS contributes to conception and design of the review. YZ contributes to study design and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Correspondence to Yinan Zhao.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hu, W., Xin, Y., Hu, J. et al. Inhibitor of DNA binding in heart development and cardiovascular diseases. Cell Commun Signal 17, 51 (2019) doi:10.1186/s12964-019-0365-z

Download citation

Keywords

  • Cardiac conduction system
  • Heart development
  • Id
  • Inhibitor of DNA binding